Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Below are the top drugs-generic stocks on the NASDAQ in terms of EPS growth forecast for the next five years.

earnings per share growth forecast for the next five years is 40.00 percent. Evoke Pharma has a market capitalization of $33.54 million.

EPS growth forecast for the next five years is 37.50 percent. Steadymed's trailing-twelve-month EPS is -$1.78.

EPS growth forecast for the next five years is 26.68 percent. Sagent Pharmaceuticals' PEG ratio is 0.91.

earnings per share growth forecast for the next five years is 23.72 percent. Akorn's trailing-twelve-month ROE is 11.10 percent.